- Home
- TRVG vs ITOS Comparison
TRVG vs ITOS Comparison
Compare TRVG & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVG
- ITOS
- Stock Information
- Founded
- TRVG 2005
- ITOS 2011
- Country
- TRVG Germany
- ITOS United States
- Employees
- TRVG N/A
- ITOS N/A
- Industry
- TRVG EDP Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRVG Technology
- ITOS Health Care
- Exchange
- TRVG Nasdaq
- ITOS Nasdaq
- Market Cap
- TRVG 306.5M
- ITOS 270.7M
- IPO Year
- TRVG N/A
- ITOS 2020
- Fundamental
- Price
- TRVG $4.85
- ITOS $6.70
- Analyst Decision
- TRVG Buy
- ITOS Strong Buy
- Analyst Count
- TRVG 4
- ITOS 3
- Target Price
- TRVG $4.88
- ITOS $25.67
- AVG Volume (30 Days)
- TRVG 250.9K
- ITOS 553.7K
- Earning Date
- TRVG 04-29-2025
- ITOS 04-28-2025
- Dividend Yield
- TRVG N/A
- ITOS N/A
- EPS Growth
- TRVG N/A
- ITOS N/A
- EPS
- TRVG N/A
- ITOS N/A
- Revenue
- TRVG $522,618,892.00
- ITOS $35,000,000.00
- Revenue This Year
- TRVG $9.05
- ITOS N/A
- Revenue Next Year
- TRVG $6.97
- ITOS $31.74
- P/E Ratio
- TRVG N/A
- ITOS N/A
- Revenue Growth
- TRVG 1.70
- ITOS 177.89
- 52 Week Low
- TRVG $1.60
- ITOS $4.80
- 52 Week High
- TRVG $5.83
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- TRVG 58.73
- ITOS 49.45
- Support Level
- TRVG $4.51
- ITOS $6.58
- Resistance Level
- TRVG $5.83
- ITOS $7.80
- Average True Range (ATR)
- TRVG 0.49
- ITOS 0.51
- MACD
- TRVG 0.12
- ITOS -0.03
- Stochastic Oscillator
- TRVG 64.87
- ITOS 32.10
About TRVG trivago N.V.
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. It derives a majority of revenue from the Developed Europe segment. The Developed Europe segment is comprised of Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Sweden, and others.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.